May 17, 2023
Through a high-throughput screen, Holly Pariury, DO, and colleagues discovered dinaciclib’s efficacy against hypodiploid Acute Lymphoblastic Leukemia (ALL) cells. The performance of viable-cell enrichment using Levitation Technology™ accelerated the lentiviral transduction-based generation of stable isogenic cell lines with altered MCL-1 levels, revealing the CDK9/MCL-1 pathway’s central role in hypodiploid ALL and a promising new treatment approach for this aggressive cancer.
April 10, 2023
Anna Bielecka-Wajdman, PhD, and colleagues investigated proteomic changes in glioblastoma multiforme (GBM) cell lines after Temozolomide (TMZ) treatment. Further, the team used the LeviCell® 1.0 system to isolate live cells that survived the treatment efficiently, enabling the characterization of this TMZ-resistant subpopulation’s morphology and growth by microscopy. The findings provide valuable insights into GBM’s treatment resistance and highlight potential therapeutic avenues.
March 20, 2023
Utilizing the LeviCell® 1.0 system, Jan Remsik, PhD, PharmD, and colleagues successfully refined the proteogenomic analysis of delicate cerebrospinal fluid samples from leptomeningeal metastasis (LM) models via CITE-seq. The breakthrough discovery that dendritic cells, guided by IFN-γ, are central to the innate immune response against leptomeningeal metastasis presents a promising direction for new therapies, highlighting the power of Levitation Technology™ in advancing cancer research.
August 11, 2015
Murat Baday, PhD, and colleagues developed a groundbreaking diagnostic tool for blood analysis that combines the power and ubiquity of smartphones with magnetic levitation-based label-free separation of red and white blood cells for quantification through cell phone imaging. The underlying technology has been developed into the LeviCell® systems for live cell enrichment and sample quality improvement through debris removal with real-time monitoring.